Angiotensin IV analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
== Applications == Because of their high mechanical, thermal and chemical stability, variable manufacturing of pore sizes with a small pore size distribution and variety of surface modifications, a wide array of applications are possible. The fact that porous glasses can be produced in many different shapes is another advantage for application in industry, medicine, pharmacy research, biotechnology and sensor technology. Porous glasses are ideal for material separation, because of the small pore size distribution. This is why they are used in gas chromatography, thin layer chromatography and affinity chromatography. An adaptation of stationary phase for a separation problem is possible by a specific modification of the surface of the porous glass. In biotechnology, porous glasses have benefits for the cleaning of DNA and the immobilization of enzymes or microorganisms. Controlled pore glass (CPG) with pore sizes between 50 and 300 nm is also excellently suited for the synthesis of oligonucleotides. In this application, a linker, a nucleoside or a non-nucleosidic compound, is first attached to the surface of CPG. The chain length of produced oligonucleotides is dependent on the pore size of CPG. In addition, porous glasses are used for manufacturing implants, especially dental implants, for which porous glass powder is processed with plastics to form a composite. The particle size and the pore size influence the elasticity of the composite so as to fit the optical and mechanical properties to surrounding tissue, for example, the appearance and hardness of dental enamel.
Warden III, who largely planned the USAF attacks; within ten minutes of the attacks by 21 F117 aircraft on 38 targets, Iraq had lost its communications and radar; Lt-Col David Deptula; in the first wave were 4 Saudi Arabian Tornado aircraft, 4 Grumman A-6 Intruder and SEAD McDonnell Douglas F-4G Wild Weasel V aircraft, 5 Northrop Grumman EA-6B Prowler aircraft to provide electronic jamming of the Iraq airspace, and 21 McDonnell Douglas F/A-18 Hornet aircraft, each which dropped the AGM-88 HARM anti-radiation missile, to destroy the Iraq surface to air missile capability; Tomahawk missiles were fired from battleships in the Gulf and submarines in the Red Sea; the General Dynamics F-111 had around four thousand gallons of fuel; before advanced guidance systems for munitions, munitions would land according to the circular error probability, which was around a half-mile for a B-17 in World War II; the first laser-guided munitions were the Pave Tack system, which debuted on the F-111 in 1982, first deployed by F-111 aircraft from RAF Lakenheath; Duncan Lennox, editor of Jane's Strategic Weapon Systems; Theodore Postol; on one evening, twenty-eight MIM-104 Patriot missiles were launched against five ballistic missiles, which had broken up on re-entry to the earth's atmosphere - hitting any of these fractured ballistic missiles was almost impossible, due to the unforeseen changing aerodynamics; Lt-Col George Cusimano, deputy director of the USAF joint; the joint also deployed synthetic-aperture radar, to give a fuller view of ground forces, from the AN/APG-76 Doppler radar; the ground picture could be relayed to ground forces, such as in the Battle of Khafji on 29 January 1991; Royal Scots 1st Battalion, with GKN Warrior tracked armoured vehicles and Major John Potter; the experimental Ferranti TIALD laser-guided munitions were deployed by RAF Panavia Tornado aircraft to destroy Iraq hardened aircraft shelters in February 1991; 39th Regiment Royal Artillery deployed the M270 Multiple Launch Rocket System (MLRS); the land battle began on 24 February 1991, watched by the DOAE in Surrey; the land war did not last long, and on 26 February 1991 retreating Iraqi vehicles and tanks were systematically destroyed by AGM-114 Hellfire missiles, launched from undetected Boeing AH-64 Apache helicopters, resulting in total destruction; the USS Wisconsin battleship fired at Failaka Island, with surveillance provided by its AAI RQ-2 Pioneer drone. Narrated by Edward Hardwicke, directed by Chris Haws, produced by Richard Melman, made by InCA Productions 18 August The Healing Mind, about the field of psychoneuroimmunology; psychiatrist Janice Kielcolt-Glaser of Ohio State University College of Medicine; psychologist Barrie R. Cassileth; chemical pathologist Malcolm Carruthers takes a blood sample from a candidate, who has been driven around Brands Hatch at 115 mph; Theodore Melnechuk of the University of California; the body's immune system - the phagocytes destroy foreign bacteria, the natural killer cells destroy the body's own cells that are too damaged, and the lymphocyte T cells and B cells remember pathogens, with a corresponding antibody; experimental psychologist Robert Ader of the University of Rochester Medical Center conducted research on rats in 1975, with cyclophosphamide, which weakens the immune system, and immunologist Nicholas Cohen; prolonged secretion of endogenous opioid peptides may lower the immune function; neuroscientist David L. Felten of the University of Rochester; psychoimmunologist Nick Hall of the University of South Florida College of Medicine and an experiment with drama students, where lowering of T cells was found; Kathleen Dillon of Western New England College, where an experiment measured Ig A of candidates who watched types of television content, and found that Ig A temporarily increased with amusing content; psychiatrist Fawzy Fawzy of the University of California; psychiatrist Margaret Kemeny of UCLA. Narrated by Geoff Watts (of Radio 4's former Science Now series, produced by Geoff Deehan in the 1970s), directed by Yavar Abbas, produced by Geoff Deehan, made by Sandlin Productions 25 August Spacesuit, the spacesuits that astronauts wore during the Apollo missions to the Moon, and whether such spacesuits would be advanced enough to be worn for future missions to Mars; by 2020, NASA expected to have landed on Mars; at sea-level, air pressure is 14 PSI; ILC Dover in Newark, Delaware has made all NASA spacesuits since the late 1960s; medical research at the Ames Research Center; Joe Kosmo, head of NASA spacesuit design; the invention of the defecation-mitten by Matthew Radnofsky; Bruce Webbon of the Ames Research Centre; the Johnson Space Center also worked on suit design. Directed by Patrick Uden, made by Uden Associates 1 September The Falls, about the Niagara Falls. Produced by Clare Odgers, made by the National Film Board of Canada and Primitive Features 8 September Re-inventing Japan, looking at Japan's success in applied science, contrasted with less success in pure science and whether Japan could enhance its pure science industry enough, which has connections with a country's own cultural values and outlook, and how Britain has excelled in pure science, but how much that university funding cuts could erode Britain's prowess in pure science; Japan few Nobel prizes, but excelled at applied science and exploiting others' research by reverse engineering; Canon had £6bn of sales, of which 40% were photocopiers, such as the L5; Hajime Mitarai, research director of Canon, and how Canon had eight product divisions, with their own engineering staff in each division, with process physicists and inorganic chemists; with Western science innovations, it often came from a set of individuals, whereas Japan's innovation culture revolved around much intense group cooperation, not individuals; Japan had only won five Nobel prizes since the 1950s - the US had won 135; a youthful Matt Ridley of The Economist; Fujitsu was the world's second-largest manufacturer of computers, and had bought ICL (which had been Ferranti) in 1990, and sold £10bn a year; Naoki Yokoyama and Takahiko Misugi of Fujitsu; Japan could not rely on other countries research anymore, and had to conduct more in-house research; Japan's culture was not greatly known for originality or taking risks, or being surprised; pathologist Sir Anthony Epstein and how Japan greatly revered tradition, and conformity, possibly viewing anyone who didn't likewise confirm as troublesome; electrical engineer Hiroya Fujisaki, of Tokyo University and known for the Fujisaki model, and that he thought that Japan's culture had historically eroded originality; the national research organisation Riken was formed in 1917, and made great progress, with a large cyclotron, and visited by Einstein in December 1922, but the US was suspicious after the war, and destroyed Riken's cyclotron; Minoru Oda, head of Riken from 1988 to 1993; the US distrusted Japan, and preferred Japan to work on mainly applied science; physicist Akira Tonomura at the Hitachi Advanced Laboratory, which had the world's largest electron microscope; Shojiro Asai of Hitachi; the Canon Advanced Research Laboratory; the Tsukuba Science City and the University of Tsukuba, built by the Japanese government for £6bn, and home of the Japanese ERATO science innovation agency; Genya Chiba, director of ERATO; Michio Nagai, former minister of education in the mid-1970s. Directed by Bob Bee, produced by Michael Wills (later Labour MP from 1997 to 2010 for North Swindon), and made by Juniper Productions 13 September Theme Park Heaven, Walt Disney; Sylvère Lotringer of Columbia University; Arrow Dynamics of California, with Dal Freeman Ron Toomer; David Lewis; Cedar Point, built by Custom Coasters International of Cincinnati; Eric Westin of Walt Disney Imagineering, and the Big Thunder Mountain Railroad ride; Marc Davis, who drew Tinkerbell in Peter Pan, and who worked on the Pirates of the Caribbean ride, which opened in 1967; Larry Lester and David Codiga of Universal Studios, and their earthquake Studio Tour and Backdraft rides; Dreamland in 1912; psychologist Timothy Leary; Douglas Trumbull and the Back to the Future: The Ride and Luxor Las Vegas; Stan Kinsey of SimEx-Iwerks; Michael Ryder and Thom Dickeson of Evans & Sutherland, and texture mapping onto polygons, a main feature of transportation simulations; Bob Stone of the Advanced Robotics Research Centre at the University of Salford. Narrated by Richard O'Brien, produced by Jerome Kuehl, directed by Graham Moore, made with WGBH and Open Media 22 September The Professor's New Clothes, a re-broadcast of an Australian documentary about Professor Vishwa Jit Gupta of Panjab University and his fraudulent work about paleontology of the Himalayas. Directed by Stephen Ramsey, produced by Janet Bell, and made by Film Australia 29 September The Gambler's Guide to Winning, the ways of deploying mathematical techniques to win in gambling, with probability theory methods developed by Prof Edward O. Thorp of University of California, Irvine; the disastrous 1967 Grand National, where nearly all the horses fell at the 23rd fence; Frank Honywill George of Brunel University; Ralph Abraham of University of California, Santa Cruz; Peter A. Griffin of California State University, Sacramento; the gambler's fallacy; J. Doyne Farmer of the Santa Fe Institute. Narrated by Andrew Burt, directed by Julian Nott (son of the Conservative former defence secretary Sir John Nott, who later composed the music for Wallace and Gromit films such as The Wrong Trousers), produced by Jenny Barraclough, made by Peninsula Films 6 October Superpowers?, with Ray Hyman, about the international group of sceptics Committee for Skeptical Inquiry, who dispute topics such as UFOs, made by Open Media 13 October The Lean Burn Machine, about the development of catalytic converters for automotive engines, and how they cause more fuel to be burned than before, and the British engineer Geoffrey West who has produced an alternative, but faced restrictions from EC (EU) legislation; Europe introduced pollution legislation in July 1992; California had the worst vehicle pollution in the US, notably LA; the Clean Air Act; Rob Searles of Johnson Matthey; German environment minister Bernd Schmidbauer - Germany had over two-thirds of European car exports to the US; French physicist Hubert Curien, Minister of Higher Education, Research and Innovation from 1988 to 1993; chemistry graduate Margaret Thatcher being interviewed on 2 March 1989 on the BBC, and lean-burn engines; Bernard Bertrand, head of engine development of Peugeot; Shillington of BL; the new EC legislation in 1992 would outlaw lean-burn powered cars; Dutch automotive writer Gerard Sauer. Narrated by Nick Ross, directed by Nick Abson and Simon Broom, produced by Michael Blakstad (Editor from 1974 of Tomorrow's World), made by Workhouse 20 October The Elements, the poet Roger McGough narrates poetry for each element and how the Periodic Table came to be formed; 5% of the Earth's crust is iron; xenon is found in strobe lights; argon is in domestic incandescent light bulbs; the light bulb filament is tungsten, but reserves of tungsten are low. Directed by Ian Duncan, produced by David Dugan, made by Windfall Films (part of Argonon). Shown on 25 November 1992 on The Nature of Things in Canada 27 October The Strange Case of Crop Circles, an update to the documentary made in 1990, looking at why the 250 crop circles that appeared in the summer, that around 50% of the circles appeared in Wiltshire; the phenomenon took off after a circle near Westbury was pictured in a local newspaper in 1980; Tim Carson charged £1 per visitor to a circle in 1990, and 7,000 visited the Eastfield Pictogram at Alton Barnes, near Milk Hill; Steve Woolgar; Sir Francis Graham-Smith of the Royal Society, who dismissed those people interested in crop circles as mixed company who talked a lot of rubbish and it was a profit-less business to get involved with people who were completely hooked on the unknown; Serena Roney-Dougal; a youthful-looking Matt Ridley of The Economist said that since episodes with nuclear power in the 1970s, people had questioned evidence that scientists had told them; physicist Terence Meaden, who founded TORRO; Yoshi-Hiko Ohtsuki of Waseda University, who researched ball lightning. Narrated by Gavin Weightman, directed by Jill Freeman, and produced by her husband Michael Wills, made by Juniper Productions 3 November Human Waste, new ways of treating excrement such as dry compost toilets, oxidation pools and greenhouses. Directed by Kate Woods (Australian), made by John Blake Associates
== Discovery == Studies conducted in the 1970s found that a series of N-formylmethionine-containing oligopeptides, including the most potent and best known member of this series, N-formylmethionine-leucyl-phenylalanine (fMLF or fMet-Leu-Phe), stimulated rabbit and human neutrophils by an apparent receptor-dependent mechanism to migrate in a directional pattern in classical laboratory assays of chemotaxis. Since these oligopeptides were produced by bacteria or synthetic analogs of such products, it was suggested that the N-formyl oligopeptides are important chemotactic factors and their receptors are important chemotactic factor receptors that act respectively as signaling and signal-recognizing elements to initiate inflammation responses in order to defend against bacterial invasion. Further studies defined a receptor for the N-formyl oligopeptides, formyl peptide receptor (FPR), so named based on its ability to bind and become activated by the oligopeptides. Two receptors where thereafter discovered and named FPR1 and FPR2 based on the similarity of their genes' predicted amino acid sequence to that of FPR rather than on any ability to bind or be activated by the formyl oligopeptides.
There are many different biosynthesis pathways to ascorbic acid in plants. Most proceed through products of glycolysis and other metabolic pathways. For example, one pathway uses plant cell wall polymers. The principal plant ascorbic acid biosynthesis pathway seems to be via l-galactose. The enzyme l-galactose dehydrogenase catalyzes the overall oxidation to the lactone and isomerization of the lactone to the C4-hydroxyl group, resulting in l-galactono-1,4-lactone. l-Galactono-1,4-lactone then reacts with the mitochondrial flavoenzyme l-galactonolactone dehydrogenase to produce ascorbic acid. l-Ascorbic acid has a negative feedback on l-galactose dehydrogenase in spinach. Ascorbic acid efflux by embryos of dicot plants is a well-established mechanism of iron reduction and a step obligatory for iron uptake. All plants synthesize ascorbic acid. Ascorbic acid is a cofactor for enzymes involved in photosynthesis, synthesis of plant hormones, as an antioxidant and regenerator of other antioxidants. Plants use multiple pathways to synthesize vitamin C. The major pathway starts with glucose, fructose or mannose (all simple sugars) and proceeds to l-galactose, l-galactonolactone and ascorbic acid. This biosynthesis is regulated following a diurnal rhythm. Enzyme expression peaks in the morning to supporting biosynthesis for when mid-day sunlight intensity demands high ascorbic acid concentrations.
Intraocular pressure can sometimes reach 80 mmHg (11 kPa). It characteristically manifests as ciliary body inflammation and massive trabecular edema that sometimes extends to Schlemm's canal. This condition is differentiated from malignant glaucoma by the presence of a deep and clear anterior chamber and a lack of aqueous misdirection. Also, the corneal appearance is not as hazy. A reduction in visual acuity can occur, followed by neuroretinal breakdown.
Sources: en.wikipedia.org
{\displaystyle {\begin{cases}{\ce {^{235}_{92}U + ^{11}_{5}B -> ^{242}_{97}Bk + 4^{1}_{0}n}}&{\ce {^{232}_{90}Th + ^{14}_{7}N -> ^{242}_{97}Bk + 4^{1}_{0}n}}\\{\ce {^{238}_{92}U + ^{10}_{5}B -> ^{242}_{97}Bk + 6^{1}_{0}n}}&{\ce {^{232}_{90}Th + ^{15}_{7}N -> ^{242}_{97}Bk + 5^{1}_{0}n}}\end{cases}}}
=== Relapsing-remitting MS === Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis and in reducing the accumulation of brain lesions, which is measured using gadolinium-enhanced magnetic resonance imaging (MRI). Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments. Nevertheless, not all the patients are responsive to these therapies. It is known that 30% of MS patients are non-responsive to Beta interferon. They can be classified in genetic, pharmacological and pathogenetic non-responders. One of the factors related to non-respondance is the presence of high levels of interferon beta neutralizing antibodies. Interferon therapy, and specially interferon beta 1b, induces the production of neutralizing antibodies, usually in the second 6 months of treatment, in 5 to 30% of treated patients. Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta 1a. While more studies of the long-term effects of the drugs are needed, existing data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes.
This could be due to their shorter generation time, higher metabolic rate, increased population structuring, increased rate of speciation, or smaller body size. When studying ancient events like the Cambrian explosion under a molecular clock assumption, poor concurrence between cladistic and phylogenetic data is often observed. There has been some work on models allowing variable rate of evolution. Models that can take into account variability of the rate of the molecular clock between different evolutionary lineages in the phylogeny are called "relaxed" in opposition to "strict". In such models the rate can be assumed to be correlated or not between ancestors and descendants and rate variation among lineages can be drawn from many distributions but usually exponential and lognormal distributions are applied. There is a special case, called "local molecular clock" when a phylogeny is divided into at least two partitions (sets of lineages) and a strict molecular clock is applied in each, but with different rates.
== Other uses == Opus (mythology), a son of Zeus Opus, Greece, a city in ancient Locris, Greece Opus (Elis), a town in ancient Elis, Greece Opus (architecture), generic term for "construction method", "construction material", "masonry", in use in Ancient Rome OPUS (chromatography), a line of chromatography columns manufactured by Repligen Corporation OPUS (psychiatry), a Danish early intervention program for people with schizophrenia spectrum disorders Opus Film, a Polish film production company
Essendon Hall of Fame Legends (year inducted): Bill Brew (2013), Bill Busbridge (1996), Jack Clarke (1996), John Coleman (1996), Bill Cookson (1996), Wally Crichton (2010), Terry Daniher (1996), Barry Davis (2006), Ron Evans (2012), Tom Fitzmaurice (1996), Ken Fraser (1996), Allan Hird Sr (1996), James Hird (2011), Harry Hunter (2015), Bill Hutchison (1996), Matthew Lloyd (2013), Simon Madden (1996), Alex McCracken (1996), Michael Long (2010), Howard Okey (2012), Frank Reid (1996), Dick Reynolds (1996), Greg Sewell (2009), Kevin Sheedy (2008), Albert Thurgood (1996), Tim Watson (1998), Neale Daniher* (2018), Dustin Fletcher*, Dr Bruce Reid* (2014), Gavin Wanganeen* *denotes recent elevation to Legend status Essendon Hall of Fame members (year inducted): Noel Allanson (2015), Fred Baring (2013), John Birt (2010), Reg Burgess (2015), Wally Buttsworth (2010), Barry Capuano (2014), Kevin Egan (2015), Alec Epis (2014), Ken Fletcher (2011), Keith Forbes (2010), Garry Foulds (2010), Darryl Gerlach (2013), Mark Harvey (2014), Bruce Heymanson (2013), Jack Jones (2012), Ron Kirwan (2016), Harold Lambert (2018), Scott Lucas (2013), Roy McConnell (2013), Don McKenzie (2010), Roger Merrett (2018), Joe Misiti (2012), Hugh Mitchell (2012), Graham Moss (2012), Gary O'Donnell (2014), Dr Ian Reynolds (2018), Paul Salmon (2012), David Shaw (2011), Arthur Showers (2010), George Stuckey (2010), Hugh Torney (2011), Paul Vander Haar (2015)
Sources: en.wikipedia.org
Hari, Johann (2015). Chasing the Scream: The First and Last Days of the War on Drugs. London; New York: Bloomsbury. ISBN 978-1-62040-890-2. Blanchard, Michael; Chin, Gabriel J. (1998). "Identifying the Enemy in the War on Drugs: A Critique of the Developing Rule Permitting Visual Identification of Indescript White Powders in Narcotics Prosecutions". American University Law Review (47): 557. SSRN 1128945. Daniel Burton-Rose, The Celling of America: An Inside Look at the U.S. Prison Industry. Common Courage Press, 1998. Stephanie R. Bush-Baskette, "The War on Drugs as a War on Black Women", in Meda Chesney-Lind and Lisa Pasko (eds.), Girls, Women, and Crime: Selected Readings. Sage, 2004. Chin, Gabriel (2002). "Race, the War on Drugs and the Collateral Consequences of Criminal Conviction". Gender, Race & Justice (6): 253. SSRN 390109. Alexander Cockburn and Jeffrey St. Clair, Whiteout: The CIA, Drugs and the Press. New York: Verso, 1998. Mitchell Earlywine, Understanding Marijuana: A New Look at the Scientific Evidence. New York: Oxford University Press, 2005. Kathleen J. Frydl, The Drug Wars in America, 1940–1973. New York: Cambridge University Press, 2013. Nunn, Kenneth B. (2002). "Race, Crime and the Pool of Surplus Criminality: Or Why the War on Drugs Was a War on Blacks". Gender, Race & Justice. 6 (6): 381. Tony Payan, "A War that Can't Be Won." Tucson: The University of Arizona Press, 2013. Preston Peet, Under the Influence: The Disinformation Guide to Drugs. The Disinformation Company, 2004. Thomas C.
For instance, an arbitrarily chosen 50-nucleotide DNA fragment encoding for the Bos taurus (cattle) albumin mRNA was subjected to test-tube evolution to derive a catalytic DNA (a deoxyribozyme, also called a DNAzyme) with RNA-cleavage activity. After only a few weeks, a DNAzyme with significant catalytic activity had evolved. In general, DNA is much more chemically inert than RNA and hence much more resistant to obtaining catalytic properties. If in vitro evolution works for DNA it will happen much more easily with RNA. In 2022, Nick Lane and coauthors showed in a computational simulation that short RNA sequences could have been capable of catalyzing CO2 fixation which supported protocell replication and growth. Amino acid-RNA ligation The ability to conjugate an amino acid to the 3'-end of an RNA in order to use its chemical groups or provide a long-branched aliphatic sidechain. It has been suggested that amino acids may have initially been involved with RNA molecules as cofactors enhancing or diversifying their enzymatic capabilities, before evolving into more complex peptides. In today's world, this is most commonly seen in the form of aminoacyl-tRNA. Peptide bond formation The ability to catalyse the formation of peptide bonds between amino acids to produce short peptides or longer proteins. This is done in modern cells by ribosomes, a complex of several RNA molecules known as rRNA together with many proteins.
== Biosynthesis == The biosynthesis of menthol has been investigated in Mentha × piperita and the enzymes involved in have been identified and characterized. It begins with the synthesis of the terpene limonene, followed by hydroxylation, and then several reduction and isomerization steps. More specifically, the biosynthesis of (−)-menthol takes place in the secretory gland cells of the peppermint plant. The steps of the biosynthetic pathway are as follows:
Dextroamphetamine is also a full agonist of trace amine-associated receptor 1 (TAAR1), a G-protein coupled receptor that regulates monoaminergic systems in the brain; activation of TAAR1 may restore impaired dopaminergic signaling in the prefrontal cortex and thereby correct deficits in inhibitory control associated with binge eating behaviors. Alongside its effect on cognitive control, appetite suppression is a common side effect of lisdexamfetamine and is associated with reduced food intake. Amphetamines are believed to dampen the sensation of hunger through actions in the lateral hypothalamus; this is thought to involve increased catecholaminergic signaling and the induction of cocaine- and amphetamine-regulated transcript (CART), a hypothalamic neuropeptide involved the regulation of food intake. While appetite suppression may influence the magnitude of reductions in food intake, three medical reviews indicate that lisdexamfetamine's enhancement of cognitive control is the primary therapeutic effect for reducing binge-eating symptoms and is likely required for addressing the disorder's underlying psychopathology. This view is supported by the failure of anti-obesity medications and other appetite suppressants to significantly reduce BED symptom severity, despite their ability to produce weight loss. Medical reviews of randomized controlled trials have demonstrated that lisdexamfetamine, at doses between 50–70 mg, is safe and effective for the treatment of moderate-to-severe BED in adults.
Across these forms, addiction is defined less by any single symptom than by a pattern: impaired control over the substance or behavior, increasing priority given to it over other activities, and continued use despite harm, accompanied for many substances by tolerance and withdrawal. It carries a substantial risk of further illness and early death, most immediately from overdose, and co-occurring psychiatric conditions are common. Roughly half of the risk of developing an addiction is genetic: twin and adoption studies estimate the heritability of alcohol use disorder at about 50%, with comparable figures across other substances. Genetic vulnerability is polygenic, reflecting the small combined effects of many common variants rather than any single gene. Environmental contributors include adverse childhood experiences, chronic stress, family and peer influences, socioeconomic constraint and the availability of substances, and adolescence in a period of heightened vulnerability. At the level of mechanism, addiction is described as a recurring cycle in which dopaminergic signaling gives a drug and its associated cues a strong pull on attention and behavior, brain stress systems become overactive as ordinary pleasures are muted, and reduced prefrontal cortex control leaves craving poorly restrained. Addiction is diagnosed clinically. The DSM-5-TR grades substance use disorder as mild, moderate, or severe and treats severe substance use disorder as synonymous with drug addiction.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.